Arvinas Inc (NASDAQ:ARVN) has earned a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the stock, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy recommendation.

Brokers have set a 12 month consensus target price of $22.00 for the company and are expecting that the company will post ($0.39) EPS for the current quarter, according to Zacks. Zacks has also assigned Arvinas an industry rank of 71 out of 255 based on the ratings given to related companies.

Several research firms have recently weighed in on ARVN. Zacks Investment Research cut Arvinas from a “hold” rating to a “sell” rating in a research note on Monday, December 24th. Goldman Sachs Group began coverage on Arvinas in a research note on Monday, October 22nd. They issued a “neutral” rating and a $17.00 price target for the company. Piper Jaffray Companies began coverage on Arvinas in a research note on Monday, October 22nd. They issued an “overweight” rating and a $23.00 price target for the company. Finally, Citigroup began coverage on Arvinas in a research note on Monday, October 22nd. They issued a “buy” rating and a $21.00 price target for the company.

Institutional investors and hedge funds have recently modified their holdings of the stock. Strs Ohio bought a new stake in shares of Arvinas in the fourth quarter worth $26,000. Gilder Gagnon Howe & Co. LLC bought a new stake in shares of Arvinas in the third quarter worth $129,000. Citadel Advisors LLC bought a new stake in shares of Arvinas in the third quarter worth $463,000. Birchview Capital LP bought a new stake in shares of Arvinas in the third quarter worth $506,000. Finally, Dean Capital Investments Management LLC bought a new stake in shares of Arvinas in the third quarter worth $631,000. 42.02% of the stock is owned by institutional investors.

ARVN stock opened at $20.49 on Friday. Arvinas has a 1-year low of $10.19 and a 1-year high of $21.47.

Arvinas Company Profile

Arvinas Holding Company, LLC, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110, proteolysis targeting chimeras (PROTAC) targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of women with metastatic ER+ breast cancer.

Featured Article: What is a blue-chip stock?

Get a free copy of the Zacks research report on Arvinas (ARVN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Arvinas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arvinas and related companies with MarketBeat.com's FREE daily email newsletter.